Literature DB >> 8423987

BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.

J Liu1, M Campbell, J Q Guo, D Lu, Y M Xian, B S Andersson, R B Arlinghaus.   

Abstract

The role of BCR gene sequences in Philadelphia (Ph) chromosome-positive leukemia is not well understood. Our previous studies demonstrated that P210 BCR-ABL co-precipitates with P160 BCR following immunoprecipitation with antibodies to the C-terminal domain of P160 BCR, sequences lacking in P210 BCR-ABL. We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. P185 BCR-ABL produced in a cell line derived from a Ph chromosome-positive acute lymphocytic leukemia patient also co-immunoprecipitated with P160 BCR. As with P210 BCR-ABL, P160 BCR tyrosine phosphopeptides were shared with P185 BCR-ABL, indicating that the major sites of tyrosine phosphorylation in vitro are contained within the first exon of P160 BCR. Similarly, BCR-ABL autophosphorylation was found to occur predominantly at tyrosines within BCR exon 1 sequences. These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423987

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.

Authors:  X Zhang; R Subrahmanyam; R Wong; A W Gross; R Ren
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Inhibition of Bcr serine kinase by tyrosine phosphorylation.

Authors:  J Liu; Y Wu; G Z Ma; D Lu; L Haataja; N Heisterkamp; J Groffen; R B Arlinghaus
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  Bcr is a negative regulator of the Wnt signalling pathway.

Authors:  Angelika Ress; Karin Moelling
Journal:  EMBO Rep       Date:  2005-10-07       Impact factor: 8.807

4.  Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.

Authors:  A W Gross; X Zhang; R Ren
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.

Authors:  J Lin; T Sun; L Ji; W Deng; J Roth; J Minna; R Arlinghaus
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

6.  Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Authors:  Geoffrey D Miller; David W Woessner; Monika J Sirch; Carol S Lim
Journal:  Mol Pharm       Date:  2013-08-20       Impact factor: 4.939

7.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

8.  Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.

Authors:  B Perazzona; H Lin; T Sun; Y Wang; R Arlinghaus
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

9.  Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS.

Authors:  Y Maru; K L Peters; D E Afar; M Shibuya; O N Witte; T E Smithgall
Journal:  Mol Cell Biol       Date:  1995-02       Impact factor: 4.272

10.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.